Drugs / Eldecalcitol
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02306187 | Dec 2014 → Dec 2022 | osteoporosis | Shinshu University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00144456 | Sep 2004 → Sep 2008 | osteoporosis | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06537115 | Jun 2024 → May 2026 overdue | muscular atrophy | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06385093 | Jun 2024 → Dec 2025 | osteoporosis, rheumatoid arthritis | Chinese SLE Treatment And Research Group | Unknown | No outcome recorded |
| Phase 4 | NCT05902078 | Sep 2023 → Jun 2025 | disease of bone structure, postmenopausal osteoporosis | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05884372 | Aug 2023 → Jul 2025 | postmenopausal osteoporosis | Xi'an Honghui Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07063797 | Feb 2026 → Jul 2027 expected | osteoporosis, type 2 diabetes mellitus | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| — | NCT01974167 | Dec 2013 → Feb 2018 | osteoporosis | e-GLORIA trial Protocol Review Committee | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03755193 Comparator | Nov 2018 → Nov 2024 overdue | osteoporosis | Shinshu University | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eldecalcitol | “A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.” PMID 21784190 ↗ Jul 20117“Eldecalcitol treatment for 24 months” NCT03755193 ↗ |
| Known as | ED-71 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00144456 ↗ |
| Known as | Edirol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02306187 ↗ |
| Known as | Gai Sheng Yuan | “Denosumab injection (Mai Lishu), 60 mg subcutaneous injection, once every six months, combined with eldecalcitol soft capsules (Gai Sheng Yuan), 0.75 μg/capsule, take one...” NCT07063797 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL4297608 ↗ |
| Modality | Small molecule | “Eldecalcitol is an analog of 1,25-dihydroxyvitamin D(3)” PMID 21784190 ↗ Jul 2011 |
| Route | Oral | “0.75μg/day(p.o.)for 144 weeks” NCT00144456 ↗ |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL4297608 ↗ |